Loss of E-Cadherin Expression and Outcome Among Patients With Resectable Pancreatic Adenocarcinomas

Modern Pathology - United Kingdom
doi 10.1038/modpathol.2011.74
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Tumour Epithelial Vimentin Expression and Outcome of Pancreatic Ductal Adenocarcinomas

British Journal of Cancer
Cancer ResearchOncology
2011English

Improving Outcomes in Patients With Resectable Pancreatic Cancer

British Journal of Surgery
Surgery
2017English

Preoperative Nomogram to Predict Survival for Patients With Resectable and Borderline Resectable Pancreatic Cancer

HPB
HepatologyGastroenterology
2017English

A Pilot Study- Neoadjuvant Chemotherapy With Gemcitabine and S1 in Patients With Resectable and Borderline Resectable Pancreatic Cancer

Journal of Carcinogenesis & Mutagenesis
2013English

Determination of Factors Predictive of Outcome for Patients Undergoing a Pancreaticoduodenectomy of Pancreatic Head Ductal Adenocarcinomas

HPB
HepatologyGastroenterology
2012English

Meta-Analysis Comparing Upfront Surgery With Neoadjuvant Treatment in Patients With Resectable or Borderline Resectable Pancreatic Cancer

British Journal of Surgery
Surgery
2018English

Refining the Predictors of Outcome in Patients With Resectable Esophageal Cancer

Cancer
Cancer ResearchOncology
2017English

Expression of Annexin A1 in Esophageal and Esophagogastric Junction Adenocarcinomas: Association With Poor Outcome

Clinical Cancer Research
Cancer ResearchOncology
2006English

An Evaluation of Neoadjuvant Chemoradiotherapy for Patients With Resectable Pancreatic Ductal Adenocarcinoma

HPB Surgery
SurgeryHepatology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy